Answers are grounded in this paper and cite their sources.
Background High-dose inactivated influenza vaccine (HD-IIV) reduces laboratory-confirmed influenza (LCI) and severe outcomes compared with standard-dose inactivated influenza vaccine (SD-IIV), but effects on patient-reported symptom burden are uncertain. Objective To compare symptom burden after HD-IIV versus SD-IIV among older adults with symptomatic LCI and assess feasibility of home-based self-swabbing with digital patient-reported outcomes. Design Prespecified exploratory substudy of the randomized, open-label DANFLU-2 trial. Setting Nationwide in Denmark within the DANFLU-2 randomized trial during the 2024 to 2025 influenza season. Participants Community-dwelling adults aged 65 years or older enrolled in DANFLU-2 who consented to participate in the Homeswab substudy. Intervention Participants were assigned 1:1 to HD-IIV or SD-IIV and received self-swab kits with digital symptom questionnaires for influenza-like illness episodes. Measurements Symptom burden among participants with LCI, assessed with the validated Respiratory Infection Intensity and Impact Questionnaire (RiiQ). Feasibility was assessed by swab return, RT-qPCR analyzability, RNase P positivity, and questionnaire completion. Results Among 10,140 randomized participants (HD-IIV, 5040; SD-IIV, 5100; mean age, 73.2 years; 50.3% female), 1280 swabs were received and 1273 were analyzable. 121 swabs (9.5%) tested positive for influenza (HD-IIV, 44; SD-IIV, 77), and RNase P positivity was 97.8% (1245 of 1273). Among participants with LCI, 97 (80.2%) completed at least 1 symptom questionnaire. Respiratory and systemic symptom severity did not differ between groups. Post hoc relative vaccine effectiveness of HD-IIV versus SD-IIV against LCI was 42.2% (95% CI, 16.4% to 60.0%). Limitations The symptom-burden analysis was limited by few breakthrough infections and incomplete questionnaire completion. Conclusion Home-based self-swabbing with digital patient-reported outcome collection was feasible at scale among older adults in a vaccine effectiveness trial, but symptom burden after LCI did not differ between HD-IIV and SD-IIV.
No takes yet. Share an insight, caveat, or question.
Davidovski et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: